The global Cardiogenic Shock Treatment Market is expected to achieve a valuation of approximately US$ 0.9 billion in 2023, with projections indicating substantial growth over the next decade. The market is anticipated to accumulate a value of US$ 1.77 billion by 2033, registering a compound annual growth rate (CAGR) of 7% during the forecast period from 2023 to 2033. The market recorded a CAGR of 3.5% during the historical period from 2018 to 2022.
The growth of the cardiogenic shock treatment market can be attributed to the rising incidence of cardiogenic shock, a serious condition often resulting from severe heart failure or myocardial infarction. As awareness of the condition increases, there is a growing demand for effective treatment strategies and technologies to manage this life-threatening emergency.
Key factors driving market expansion include advancements in treatment modalities such as mechanical circulatory support devices, intra-aortic balloon pumps, and pharmacological therapies that enhance cardiac output and stabilize patients. Additionally, the increasing prevalence of risk factors associated with cardiogenic shock, such as hypertension, diabetes, and coronary artery disease, is further propelling market growth.
North America currently dominates the cardiogenic shock treatment market, supported by advanced healthcare infrastructure, significant investments in cardiovascular research, and a high prevalence of heart-related conditions. The Europe region is also witnessing considerable growth due to improved diagnostic techniques and the availability of innovative treatment options.
As the cardiogenic shock treatment market continues to evolve, stakeholders are expected to focus on research and development initiatives aimed at introducing new therapies and enhancing existing treatment protocols. The future of the cardiogenic shock treatment market appears promising, with opportunities for improved patient outcomes and effective management of this critical condition.
What are the Challenges Faced by the Cardiogenic Shock Treatment Market?
Expensive Cost of Treatment to restrict Market Growth
The cost of treatment for cardiogenic shock can be significant, particularly for mechanical support devices such as Impella and ECMO. This can limit access to these treatments for some patients and may also impact market growth. Additionally, the development and approval of new treatments for cardiogenic shock can be a lengthy and costly process, which can limit the availability of new treatment options and contribute to market stagnation.
Market Competition
Key players in the market include companies such as Getinge AB, Par Pharmaceutical, Abbott, Viatris Inc., F. Hoffman-La Roche Ltd, Bayer AG, Terumo Corporation, Medtronic, AbioMed, Astrazeneca along with healthcare providers and technology companies among other global players.
- In October 2022, the American Heart Association established the Cardiogenic Shock Registry, powered by Get With The Guidelines®, to provide a foundation for researchers, clinicians, and regulators to better understand the clinical symptoms, treatment patterns, and outcomes of different types of shock. The registry builds on over two decades of experience with the Get With The Guidelines® platform and will inform the medical community on how to best treat cardiogenic shock. The steering committee of the registry includes experts from leading academic surgeons and cardiologists, as well as representatives from the USA Food & Drug Administration and the USA Centers for Medicare & Medicaid Services, who provide guidance on establishing and managing the data in the registry.
Key Companies Profiled
Getinge AB, Par Pharmaceutical, Abbott, Viatris Inc., F. Hoffman-La Roche Ltd, Bayer AG, Terumo Corporation, Medtronic, AbioMed, Astrazeneca
Key Segments Profiled in the Cardiogenic Shock Treatment Industry Survey
Treatment Type:
- In-Vitro Test Kits
- Drugs
- Devices
End- User:
- Cardiac Catheterization Labs
- Hospitals
- Ambulatory Surgical Centres
Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
